TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 100nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 550nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 1/Serine/threonine-protein kinase B-raf(Human)
Ikena Oncology
US Patent
Ikena Oncology
US Patent
Affinity DataIC50: 5.50E+3nMAssay Description:Table 3: Compound effects on binding affinity of MEK to BRAF or CRAF were followed by surface plasmon resonance (SPR) with single-cycle kinetic analy...More data for this Ligand-Target Pair












3D Structure (crystal)



























